29th Mar 2018 09:33
West-Ward's Palonosetron HCI Injection is a serotonin-3 (5-HT3) receptor antagonist indicated in adults for moderately emetogenic cancer chemotherapy - for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses - and for highly emetogenic cancer chemotherapy and the prevention of acute nausea and vomiting associated with initial and repeat courses.
"We are very pleased to add Palonosetron HCI Injection to our oncology portfolio. The launch of this product further expands our broad Injectables portfolio, bringing value to our customers and patients in the US hospital setting, as well as driving long-term, sustainable growth for our business," said Hikma Riad Mechlaoui, chief executive officer of the Injectables Division.
Shares in Hikma were up 1.8% at
Related Shares:
Hikma Pharmaceuticals